Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter November 22, 2016

CYP2D6 variability in populations from Venezuela

  • Nancy Moreno EMAIL logo , Carlos Flores-Angulo , Cecilia Villegas and Yuselin Mora


CYP2D6 is an important cytochrome P450 enzyme that plays an important role in the metabolism of about 25% of currently prescribed drugs. The presence of polymorphisms in the CYP2D6 gene may modulate enzyme level and activity, thereby affecting individual responses to pharmacological treatments. The most prevalent diseases in the admixed population from Venezuela are cardiovascular and cancer, whereas viral, bacterial and parasitic diseases, particularly malaria, are prevalent in Amerindian populations; in the treatment of these diseases, several drugs that are metabolized by CYP2D6 are used. In this work, we reviewed the data on CYP2D6 variability and predicted metabolizer phenotypes, in healthy volunteers of two admixed and five Amerindian populations from Venezuela. The Venezuelan population is very heterogeneous as a result of the genetic admixture of three major ethnical components: Europeans, Africans and Amerindians. There are noticeable inter-regional and inter-population differences in the process of mixing of this population. Hitherto, there are few published studies in Venezuela on CYP2D6; therefore, it is necessary to increase research in this regard, in particular to develop studies with a larger sample size. There is a considerable amount of work remaining before CYP2D6 is integrated into clinical practice in Venezuela.


We are grateful to Dr. Flor Herrera from Instituto de Investigaciones Biomédicas “Dr. Francisco J. Triana Alonso” for useful suggestions. I would like to thank Prof. Willie Peterson for revising the English in the manuscript.

  1. Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved the submission.

  2. Research funding: This study was financed by Fondo Nacional de Ciencia y Tecnología (FONACIT) through of the project N° 2012001248.

  3. Employment or leadership: None declared.

  4. Honorarium: None declared.

  5. Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.


1. Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part I. Clin Pharmacokinet 2009;48:689–23.10.2165/11318030-000000000-00000Search in Google Scholar PubMed

2. The Human Cytochrome P450 (CYP) Allele Nomenclature Database. CYP2D6 allele nomenclature. Available at: Accessed: 25 May 2016.Search in Google Scholar

3. Brauch H, Mürdter TE, Eichelbaum M, Schwab M. Pharmacogenomics of tamoxifen therapy. Clin Chem 2009;55:1770–82.10.1373/clinchem.2008.121756Search in Google Scholar PubMed

4. Llerena A, Naranjo ME, Rodrigues-Soares F, Penas-Lledó EM, Fariñas H, Tarazona-Santos E. Interethnic variability of CYP2D6 alleles and of predicted and measured metabolic phenotypes across world populations. Expert Opin Drug Metab Toxicol 2014;10:1569–83.10.1517/17425255.2014.964204Search in Google Scholar PubMed

5. Céspedes-Garro C, Jiménez-Arce G, Naranjo ME, Barrantes R, Llerena A, CEIBA. FP Consortium of the Ibero-American Network of Pharmacogenetics and Pharmacogenomics RIBEF. Ethnic background and CYP2D6 genetic polymorphisms in Costa Ricans. Rev Biol Trop 2014;62:1659–71.10.15517/rbt.v62i4.12916Search in Google Scholar

6. Dorado P, Heras N, Machín E, Hernández F, Teran E, Llerena A. CYP2D6 genotype and dextromethorphan hydroxylation phenotype in an Ecuadorian population. Eur J Clin Pharmacol 2012;685:637–44.10.1007/s00228-011-1147-8Search in Google Scholar PubMed

7. Isaza CA, Henao J, López AM, Cacabelos R. Isolation, sequence and genotyping of the drug metabolizer CYP2D6 gene in the Colombian population. Methods Find Exp Clin Pharmacol 2000;22:695–05.10.1358/mf.2000.22.9.802286Search in Google Scholar PubMed

8. Ministerio del Poder Popular para la Salud (MPPS). Anuario de mortalidad 2011. Available at: Accessed: 12 May 2016.Search in Google Scholar

9. Cáceres JL. Récord de incidencia malárica en Venezuela. Bol Mal Salud Amb 2013;53:88–98.Search in Google Scholar

10. World Health Organization Guidelines for the treatment of malaria 3rd edition. Available at: eng.pdf?ua=1&ua=1. Accessed: 5 July 2016.Search in Google Scholar

11. Griman P, Moran Y, Valero G, Loreto M, Borjas L, Chiurillo MA. CYP2D6 gene variants in urban/admixed and Amerindian populations of Venezuela: pharmacogenetics and anthropological implications. Ann Hum Biol 2012;39:137–42.10.3109/03014460.2012.656703Search in Google Scholar PubMed

12. Flores-Angulo C, Villegas C, Mora Y, Martínez JA, Oropeza T, Moreno N. Variantes alélicas de CYP2D6: *4, *6 y *10 en una muestra de residentes del estado Aragua, Venezuela. Rev Peru Med Exp Salud Pública 2015;32:746–51.10.17843/rpmesp.2015.324.1767Search in Google Scholar

13. Salcedo-Bastardo JL. Historia Fundamental de Venezuela. Caracas: Universidad Central de Venezuela. Ediciones de la Biblioteca, 1996:649.Search in Google Scholar

14. Acosta M. Vida de los esclavos negros en Venezuela. Caracas: Hespérides Ediciones, 1967:410.Search in Google Scholar

15. Vargas I. Diversidad y mestizaje en Venezuela. Available at: Accessed: 4 Sep 2016.Search in Google Scholar

16. Castro de Guerra D, Zambrano O. Aporte génico español canario en tres poblaciones semiaisladas venezolanas. Estimaciones hechas a partir de los sistemas ABO, RH y Alfa-1-Antitripsina. Rev Esp Antropol Biol 2000;21:111–18.Search in Google Scholar

17. Rodríguez-Larralde A, Castro de Guerra D, González M, Morales, J. Frecuencia génica y porcentaje de mezcla en diferentes áreas geográficas de Venezuela, de acuerdo a los grupos RH y ABO. Interciencia 2001;26:8–12.Search in Google Scholar

18. Moreno N, Martínez JA, Blanco Z, Osorio L, Hackshaw P. Beta-globin gene cluster haplotypes in Venezuelan sickle cell patients from the of Aragua. Genet Mol Biol 2002;25:21–4.10.1590/S1415-47572002000100005Search in Google Scholar

19. Martínez H, Rodríguez-Larralde A, Izaguirre MG, Castro De Guerra D. Admixture estimates for Caracas, Venezuela, based on autosomal, Y-Chromosome, and mtDNA markers. Human Biol 2007;79:201–13.10.1353/hub.2007.0032Search in Google Scholar PubMed

20. Rodríguez-Larralde A, Morales J, Barrai I. Surname frequency and the isonymy structure of Venezuela. Am J Hum Biol 2000;12:352–62.10.1002/(SICI)1520-6300(200005/06)12:3<352::AID-AJHB5>3.0.CO;2-SSearch in Google Scholar

21. Instituto Nacional de Estadística (INE). República Bolivariana de Venezuela: XIV Censo Nacional de Población y Vivienda, Resultados Básicos, Total Nacional y Entidades Federales. Available at: pdf/Censo%202011_ Resultados_Basicos.pdf. Accessed: 15 May 2016.Search in Google Scholar

22. Moya G, Dorado P, Ferreiro V, Naranjo ME, Peñas-Lledó EM, Llerena A. High frequency of CYP2D6 ultrarapid metabolizer genotypes in an Ashkenazi Jewish population from Argentina. Pharmacogenomics J 2016. Doi: 10.1038/tpj2016.27. [Epub ahead of print].10.1038/tpj2016.27Search in Google Scholar

23. Llerena A, Dorado P, Ramírez R, González I, Alvarez M, Peñas-Lledó EM, et al. CYP2D6 genotype and debrisoquine hydroxylation phenotype in Cubans and Nicaraguans. Pharmacogenomics J 2012;12:176–83.10.1038/tpj.2010.85Search in Google Scholar

24. Perez-Paramo YX, Hernandez-Cabrera F, Dorado P, Llerena A, Muñoz-Jimenez S, Ortiz-Lopez R, et al. Interethnic relationships of CYP2D6 variants in native and Mestizo populations sharing the same ecosystem. Pharmacogenomics 2015;16:703–12.10.2217/pgs.15.24Search in Google Scholar

25. Naranjo ME, de Andrés F, Delgado A, Cobaleda J, Peñas-Lledó EM, LLerena A. High frequency of CYP2D6 ultrarapid metabolizers in Spain: controversy about their misclassification in worldwide population studies. Pharmacogenomics J 2016;16:485–90.10.1038/tpj.2016.47Search in Google Scholar

26. Albuquerque J, Ribeiro C, Naranjo M, Llerena A, Grazina M, CEIBA.FP Consortium of the Ibero–American Network of Pharmacogenetics & Pharmacogenomics RIBEF. Characterization of CYP2D6 genotypes and metabolic profiles in the Portuguese population: pharmacogenetic implications. Per Med 2013;10:709–18.10.2217/pme.13.56Search in Google Scholar

27. Jorge LF, Eichelbaum M, Griese EU, Inaba T, Arias TD. Comparative evolutionary pharmacogenetics of CYP2D6 in Ngawbe and Embera Amerindians of Panama and Colombia: role of selection versus drift in world populations. Pharmacogenetics 1999;9:217–28.Search in Google Scholar

28. Lizarralde M, Lizarralde R. A Cruel Peace: The Barí Epidemics after Contact. Tipití: SALSA. 2016;14:44–71. Available at: tipiti/vol14/iss1/4. Accessed: 5 Sep 2016.Search in Google Scholar

29. Nassan M, Nicholson WT, Elliott MA, Rohrer Vitek CR, Black JL, Frye MA. Pharmacokinetic prescribing guidelines for antidepressants: a template for psychiatric precision medicine. Mayo Clin Proc 2016;91:897–07.10.1016/j.mayocp.2016.02.023Search in Google Scholar

30. Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther 2008;832:234–42.10.1038/sj.clpt.6100406Search in Google Scholar

31. Ng CG, Boks MP, Zainal NZ, de Wit NJ. The prevalence and pharmacotherapy of depression in cancer patients. J Affect Disord 2011;131:1–7.10.1016/j.jad.2010.07.034Search in Google Scholar

32. Ministerio del Poder Popular para la Salud. Boletín integral de salud ambiental. Semana epidemiológica 53, 2014. Available at: Accessed: 5 Sep 2016.Search in Google Scholar

33. Bergamo L, Bolívar E, Godoy A, Carrero N, Betancourt L, Romero G, et al. Tratamiento preservador del cáncer de la mama: dos años de experiencia. Rev Venez Oncol 2011;23:46–9.Search in Google Scholar

34. Del Re M, Citi V, Crucitta S, Rofi E, Belcari F, van Schaik RH, et al. Pharmacogenetics of CYP2D6 and tamoxifen therapy: light at the end of the tunnel? Pharmacol Res 2016;107:398–406.10.1016/j.phrs.2016.03.025Search in Google Scholar

35. Zahari Z, Ismail R. Influence of cytochrome P450, family 2, subfamily D, polypeptide 6 (CYP2D6) polymorphisms on pain sensitivity and clinical response to weak opioid analgesics. Drug Metab Pharmacokinet 2014;29:29–43.10.2133/dmpk.DMPK-13-RV-032Search in Google Scholar

36. Bennett JW, Pybus BS, Yadava A, Tosh D, Sousa JC, McCarthy W, et al. Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria. N Engl J Med 2013;369:1381–2.10.1056/NEJMc1301936Search in Google Scholar PubMed

37. Hicks JK, Bishop JR, Sangkuhl K, Müller DJ, Ji Y, Leckband SG, et al. Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin Pharmacol Ther 2015;98:127–34.10.1002/cpt.147Search in Google Scholar PubMed PubMed Central

38. Swen JJ, Nijenhuis M, de Boer A, Grandia L, Maitland-van der Zee AH, Mulder H, et al. Pharmacogenetics: from bench to byte – an update of guidelines. Clin Pharmacol Ther 2011;89:662–73.10.1038/clpt.2011.34Search in Google Scholar PubMed

39. Food and Drug Administration–USA (FDA). Table of Pharmacogenomic Biomarkers in Drug Labeling Available at: Accessed: 5 July 2016.Search in Google Scholar

40. Quiñones LA, Lavanderos MA, Cayun JP, Garcia-Martin E, Agundez JA, Caceres DD, et al. Perception of the usefulness of drug/gene pairs and barriers for pharmacogenomics in Latin America. Curr Drug Metab 2014;15:202–8.10.2174/1389200215666140202220753Search in Google Scholar PubMed

Received: 2016-7-23
Accepted: 2016-11-2
Published Online: 2016-11-22
Published in Print: 2016-12-1

©2016 Walter de Gruyter GmbH, Berlin/Boston

Downloaded on 21.2.2024 from
Scroll to top button